WASHINGTON, July 24, 2003 (PRIMEZONE) -- Growth Report, an independent investment newsletter service for individual investors that has delivered returns of 48.6% in the first half of 2003, today announced the addition of Bio-Imaging (AMEX:BIT) to its stock portfolio.
Bio-Imaging is a leading provider of medical imaging management services that support the product development and regulatory approval process of pharmaceutical, biotechnology, and medical device companies.
Growth Report added Bio-Imaging to the model portfolio on July 23 at $6.15. This initial research report is available on the Growth Report web site free of charge to trial subscribers at http://www.growthreport.com/
The report discusses:
-- The medical imaging market
-- Benefits to pharmaceutical and medical device companies that
utilize outsourced imaging services
-- First quarter financial results
-- Bio-Imaging's leading medical imaging solutions
-- Revenue and earnings per share guidance for 2003
In the July 23rd issue of Growth Report, Editor Ian Wyatt wrote, "We believe the future is bright for Bio-Imaging, and that early investors will be well rewarded in the long-term for placing their bets with this company. We believe revenue and earnings growth of 25-30% is achievable, given the strong demand for outsourced services in the biotechnology and pharmaceutical sector, desire of companies to expedite the regulatory submission process, the company's increasing backlog of revenue, and management's ability to deliver strong growth and results in the previous quarters."
Growth Report has a history of following companies in the medical imaging space with its coverage of Vital Images (Nasdaq:VTAL). On a valuation basis, Vital Images trades at nearly 80-times 2003 consensus earnings per share estimates and 7.5-times 2003 revenue estimates, versus Bio-Imaging shares which trade at 2.2-times our revenue estimate and 36-times our earnings per share estimate for this year.
Growth Report's stock portfolio returned 40% in 2002, and is up another 48.6% in the first half of 2003 by taking long-term positions in fundamentally strong growth stocks. This investment approach has yielded consistently strong returns for subscribers of the newsletter service.
Individual investors who are interested in signing up for a 30-day free trial to Growth Report will receive this report on Bio-Imaging, plus a free Special Report titled "Not So Generic Returns -- Investing in Generic and Specialty Pharmaceuticals." Free trial subscribers also receive two issues per week by e-mail, one issue per month in print, access to over one year of archived articles, and past and future Special Reports. To start a free 30-day trial subscription, click here: https://www.bizfn.com/index.cfm?Page=pubs&pubs=2&r=pr5
About Growth Report
Growth Report is a leading investment newsletter service published by Business Financial Publishing, LLC. Growth Report is entirely independent, and dedicated to uncovering stocks that will deliver the greatest return to subscribers. Two weekly issues delivered by e-mail and on the web provide subscribers with regular updates on the latest news and changes to the portfolio, while a monthly print edition provides in depth articles in an easy to read format.
Disclaimer
Growth Report is neither a registered investment advisor nor a broker / dealer. Readers are advised that the publication is issued solely for information purposes and should not to be construed as an offer to sell or the solicitation of an offer to buy any security. No information provided herein or elsewhere from Growth Report constitutes a recommendation by Growth Report to buy, sell or hold any security. We encourage you to consult with independent financial advisors with respect to any investment in the securities mentioned herein.